Last updated: August 28, 2026
Gallium chloride Ga-67 is not a pharmaceutical excipient. It is a radioactive gallium-67 source used in diagnostic nuclear medicine, either as gallium citrate Ga-67 for direct administration or as a labeling precursor for radiopharmaceutical preparation. Its commercial market is mature, specialized and declining in conventional oncology and infection imaging. Revenue is constrained by low procedure volumes, short shelf life, cyclotron dependence and competition from fluorine-18 PET, gallium-68 PET and newer targeted radiopharmaceuticals. Public companies generally do not report Ga-67 revenue separately, so a defensible standalone market-size or revenue forecast is not available.
What is gallium chloride Ga-67 used for?
Gallium chloride Ga-67 is a radiopharmaceutical intermediate or active radionuclide source, not an inactive formulation ingredient.
Gallium-67 is produced by cyclotron irradiation, commonly through proton bombardment of enriched zinc-68. The radionuclide has a half-life of approximately 78.3 hours and emits gamma radiation suitable for planar imaging and single-photon emission computed tomography (SPECT) [1].
Its historical applications include:
- Localization of certain tumors, particularly lymphoma and other malignancies.
- Imaging of infection and inflammation.
- Evaluation of fever of unknown origin.
- Radiolabeling of compounds used in research or specialized diagnostic procedures.
The administered diagnostic product in the United States has historically been gallium citrate Ga-67 injection rather than a generic "gallium chloride" finished dosage form. Gallium chloride solutions are more commonly associated with radiopharmaceutical manufacturing and labeling processes.
Is gallium chloride Ga-67 an excipient?
No. An excipient is an inactive ingredient used to formulate a drug. Gallium-67 is the radioactive active component or labeling isotope. Hydrochloric acid, sodium citrate, sodium chloride and other formulation materials may appear in a Ga-67 product, but gallium chloride itself is not an excipient in the regulatory sense.
How large is the gallium chloride Ga-67 market?
The standalone market is small and opaque. Public industry reports often group Ga-67 with broader categories such as diagnostic radiopharmaceuticals, medical isotopes or nuclear medicine products. Those reports rarely distinguish:
- Gallium-67 from gallium-68.
- Gallium chloride from gallium citrate.
- Isotope sales from finished radiopharmaceutical sales.
- Manufacturing revenue from hospital radiopharmacy revenue.
The addressable market is therefore better measured through procedure demand, installed imaging capacity and recurring isotope supply rather than reported product revenue.
| Market factor |
Effect on Ga-67 |
| Product maturity |
Limits pricing growth and new investment |
| 78.3-hour half-life |
Permits regional distribution but creates decay-related waste |
| Cyclotron production |
Restricts supply to specialized manufacturers |
| SPECT dependence |
Places Ga-67 at a disadvantage to PET imaging |
| Gallium-68 growth |
Diverts investment toward newer gallium radiopharmaceuticals |
| Generic and legacy-product status |
Reduces differentiation and pricing power |
| Hospital demand |
Concentrated in academic and specialized nuclear-medicine centers |
Ga-67 remains commercially relevant in selected markets, but it is no longer a major growth platform for diagnostic imaging.
What is driving the market decline?
PET has replaced many historical Ga-67 applications
Fluorine-18 fluorodeoxyglucose PET has displaced much of the historical role of Ga-67 in oncology and infection imaging. PET generally provides higher sensitivity, better spatial resolution and faster imaging workflows than conventional gallium scintigraphy.
In lymphoma, FDG PET/CT is established for staging and treatment-response assessment. In infection and inflammation, FDG PET/CT and labeled leukocyte imaging compete with Ga-67. Clinical guidelines and hospital purchasing decisions therefore favor PET where equipment and reimbursement are available [2].
Gallium-68 is creating a separate, higher-growth isotope market
Gallium-68 has a half-life of approximately 67.7 minutes and is used to label targeted molecules such as DOTATATE and prostate-specific membrane antigen ligands. FDA-approved gallium-68 products include Ga-68 DOTATATE and Ga-68 gozetotide products for PET imaging [3][4].
Ga-68 is not a direct chemical substitute for Ga-67. The isotopes have different half-lives, imaging characteristics, production logistics and clinical uses. They compete for:
- Cyclotron and generator investment.
- Radiopharmacy manufacturing capacity.
- Nuclear-medicine capital budgets.
- Physician attention and reimbursement.
- Hospital PET scheduling capacity.
The commercial growth of Ga-68 has not expanded the Ga-67 market. It has increased investor and manufacturer focus on targeted PET radiopharmaceuticals instead.
Manufacturing economics are unfavorable
Ga-67 production requires a qualified cyclotron, enriched target material, radiochemical processing and validated quality-control procedures. Manufacturers must manage:
- Target irradiation.
- Radionuclidic purity.
- Chemical purity.
- Sterility and endotoxin control.
- Transport before excessive radioactive decay.
- Batch-release timing.
- Radioactive waste.
The relatively long half-life compared with Ga-68 supports regional distribution, but every hour between production, release, shipment and administration reduces usable activity. Low procedure volume can make batch economics difficult because fixed production and compliance costs are spread across fewer doses.
What is the financial trajectory for Ga-67?
The financial trajectory is best characterized as a declining legacy market with stable residual demand.
| Period |
Financial direction |
Main explanation |
| Historical peak |
Expansion |
Ga-67 was widely used for tumor and infection imaging |
| 2000s-2010s |
Decline |
FDG PET/CT reduced demand in oncology |
| 2020s |
Mature and fragmented |
Residual use persists in specialized centers |
| Medium term |
Gradual erosion |
Ga-68 PET, FDG PET and other modalities capture investment |
| Long term |
Niche or regional survival |
Demand may persist where PET access is limited or clinical practice remains established |
No major listed manufacturer discloses a separate Ga-67 revenue line in public filings. Reported revenue is usually aggregated within nuclear medicine, imaging agents, contract manufacturing or isotope operations. Product-specific revenue estimates would therefore require proprietary shipment, procedure or distributor data.
Pricing and margin profile
Ga-67 pricing is influenced by dose activity, delivery distance, production schedule and local reimbursement. The product has limited ability to sustain premium pricing because:
- The clinical indication is mature.
- Several imaging alternatives exist.
- The product is generally not protected by meaningful modern composition-of-matter exclusivity.
- Hospitals can substitute imaging modalities where infrastructure permits.
- Decay creates inventory and logistics losses.
Margins can remain acceptable for suppliers with existing cyclotron infrastructure and regional distribution networks. New entrants face higher qualification and regulatory costs without a comparable growth opportunity.
Who supplies gallium chloride Ga-67?
Supply is concentrated among specialized radiopharmaceutical manufacturers, medical-isotope producers and hospital or academic cyclotron facilities. The relevant competitive set can include:
- Commercial nuclear-medicine manufacturers.
- Contract radiopharmaceutical producers.
- National isotope agencies.
- Regional cyclotron operators.
- Hospital-based radiopharmacies.
- Research institutions producing investigational labeled compounds.
Supplier identity varies substantially by country. Regulatory approval of the radionuclide source, manufacturing site, radiochemical process and finished dosage form is jurisdiction-specific.
A supplier’s competitive position depends less on conventional pharmaceutical branding than on:
- Cyclotron location.
- Access to enriched zinc targets.
- Validated radiochemical production.
- Distribution radius.
- Regulatory licenses.
- Hospital contracts.
- Ability to provide reliable delivery schedules.
What is the FDA regulatory status of Ga-67?
The FDA has regulated gallium citrate Ga-67 injection as a diagnostic radiopharmaceutical for specific tumor and inflammation-related imaging uses. The product is administered intravenously and contains radioactive gallium associated with a citrate complex.
The regulatory profile differs from standard small-molecule pharmaceuticals because production, transport and use are also subject to radioactive-material controls. In the United States, the FDA regulates the drug product while state authorities or the Nuclear Regulatory Commission regulate aspects of radioactive-material possession and use, depending on the facility and jurisdiction [5].
Is gallium chloride Ga-67 in the Orange Book?
A gallium chloride precursor is not generally an Orange Book-style reference product with a conventional patent-based generic-entry profile. Orange Book relevance depends on the specific FDA-approved finished drug product and its listed patents or exclusivity.
For a legacy Ga-67 product, the commercial barriers are more likely to involve:
- Manufacturing-site approval.
- Sterility and quality systems.
- Radioactive-material licensing.
- Cyclotron access.
- Distribution controls.
- Product-specific regulatory filings.
These barriers are operational and regulatory rather than patent-driven.
What patents protect gallium chloride Ga-67?
The core radioactive isotope and its diagnostic use are not likely to support meaningful modern patent exclusivity. Gallium-67, gallium citrate chemistry and conventional imaging applications have long histories that place basic composition and use claims outside ordinary new-drug patent terms.
Potentially relevant intellectual property may instead cover:
- Radiolabeling methods.
- Chelators.
- Targeted ligands.
- Automated synthesis equipment.
- Purification systems.
- Sterile filling processes.
- Quality-control methods.
- Combination products using Ga-67.
Those rights would generally protect a specific labeled compound, process or device, not gallium chloride Ga-67 as a commodity radionuclide. No reliable conclusion about active patent numbers, expiration dates or freedom to operate can be made without a defined jurisdiction and product presentation.
Are there Paragraph IV challenges or generic-entry risks?
A conventional Paragraph IV challenge is unlikely to be the main commercial issue for gallium chloride Ga-67. Paragraph IV litigation applies to an abbreviated new drug application challenging listed patents for an FDA reference product. Legacy radiopharmaceutical products may instead face:
- 505(b)(2) applications.
- Full new drug applications.
- Drug-master-file and contract-manufacturing arrangements.
- Site-specific regulatory review.
- Hospital compounding or radiopharmacy rules.
The principal generic-entry risk is price competition from another approved supplier with equivalent radiochemical quality and reliable delivery. The principal launch risk is supply execution, not patent invalidity.
What geographic markets remain attractive?
Ga-67 has stronger residual value in regions where PET capacity is limited or where SPECT-based nuclear medicine remains embedded in clinical practice.
| Geographic factor |
Commercial implication |
| High PET availability |
Faster substitution away from Ga-67 |
| Limited PET infrastructure |
Longer residual Ga-67 demand |
| Local cyclotron capacity |
Lower shipping and decay losses |
| Strong academic nuclear medicine |
Continued specialized use |
| Fragmented reimbursement |
Variable procedure economics |
| Strict radioactive-material controls |
Higher entry costs |
The market is therefore geographically fragmented. A product may be commercially viable in a country or region with limited PET access even as demand declines in the United States, Western Europe and other mature PET markets.
How does Ga-67 compare with Ga-68?
| Attribute |
Ga-67 |
Ga-68 |
| Primary imaging |
SPECT or planar imaging |
PET/CT or PET/MRI |
| Half-life |
About 78.3 hours |
About 67.7 minutes |
| Main uses |
Legacy tumor, infection and inflammation imaging |
Targeted oncology PET |
| Market position |
Mature and declining |
Growing within radioligand imaging |
| Distribution |
Regional shipment feasible |
Generator or nearby cyclotron preferred |
| Investment outlook |
Defensive and niche |
Higher strategic interest |
| Patent activity |
Mostly legacy or process-related |
Active around ligands, chelators and methods |
Ga-68 has the stronger commercial trajectory because its value is linked to targeted molecular imaging and radioligand therapy ecosystems. Ga-67 remains a specialized diagnostic product without the same platform economics.
Key Takeaways
- Gallium chloride Ga-67 is a radiopharmaceutical isotope source, not a pharmaceutical excipient.
- The market is mature, small and declining in most developed imaging systems.
- FDG PET and Ga-68 targeted PET are the main competitive pressures.
- Standalone revenue is not disclosed reliably by public companies.
- Manufacturing economics depend on cyclotron access, radiochemistry, quality systems and regional delivery.
- Patent risk is limited for the legacy isotope itself; operational and regulatory barriers are more important.
- Paragraph IV litigation and Orange Book patent disputes are unlikely to define market entry.
- Residual demand is strongest in specialized centers and regions with limited PET availability.
- Ga-67 has a defensive niche trajectory, while Ga-68 has the stronger growth and investment profile.
FAQs
Is gallium chloride Ga-67 the same as gallium citrate Ga-67?
No. Gallium chloride is commonly a radionuclide source or radiolabeling precursor. Gallium citrate Ga-67 is a finished diagnostic radiopharmaceutical formulation used for administration and imaging.
Can gallium-67 be used in PET scans?
No. Gallium-67 is primarily used with planar imaging and SPECT because of its photon-emission profile. Gallium-68 is the gallium isotope commonly used for PET.
Does gallium chloride Ga-67 have biosimilar competition?
No. Biosimilar rules apply to biologic products. Ga-67 products are radioactive small-molecule or radiopharmaceutical products and do not follow the biosimilar pathway.
What is the main barrier to launching a Ga-67 product?
The main barriers are licensed cyclotron production, validated radiochemical manufacturing, sterile release, radioactive-material authorization and dependable regional distribution.
Is Ga-67 a growth investment within nuclear medicine?
Generally no. Ga-67 is a mature niche product. Growth-oriented investment in nuclear medicine is more closely associated with Ga-68, fluorine-18 agents, targeted radioligand therapy and theranostic manufacturing platforms.
References
-
International Atomic Energy Agency. (2020). Cyclotron produced radionuclides: Physical characteristics and production methods. IAEA.
-
National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: B-cell lymphomas. NCCN.
-
U.S. Food and Drug Administration. (2016). NETSPOT (gallium Ga 68 dotatate) injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (2023). LOCAMET (gallium Ga 68 gozetotide) injection prescribing information. FDA.
-
U.S. Nuclear Regulatory Commission. (2024). Medical use of radioactive material. NRC.
